Mainly, dynamic increase in sPD-1 after anti-PD-1 treatment has been significantly associated with disease progression, indicating that as sPD-1 levels increase, it strengthens T cell inhibition and cancer immune evasion, thus resulting in poor outcome (18, 19, 96). Here, HOXD13 is linked to cancer.